The Chiodo Companies Announce Partnership with Roche Diagnostics
News Apr 20, 2007
The Chiodo Companies, Inc. announced a strategic partnership with Roche Diagnostics aimed at setting and advancing a DNA-based standard for mold detection. The partnership encompasses a joint marketing effort and the co-development of customized solutions targeted at both the commercial and end user markets.
Effective immediately, Clean Air Labs, The Chiodo Companies’ R&D and analysis laboratory, will move its real-time Polymerase Chain Reaction (PCR) analysis to the Roche Diagnostics platform. Clean Air Inspections, the environmental consulting arm of The Chiodo Companies, Inc, will continue working with its clients to transition from spore-trap sampling, to a sampling methodology better suited for DNA analysis.
DNA-based mold detection using quantitative real-time PCR has been shown to be superior to the widely used spore trap methodology. This DNA-PCR method, developed and patented by scientists at the United States Environmental Protection Agency (US-EPA), provides simple and standardized alternative for mold analysis that can reduce uncertainties in interpretation of results.
The recently licensed EPA assay utilizes a panel of genetic markers from key species of molds associated with water intrusion, that are of particular importance to building owners and occupants. Each DNA sample tested by Clean Air Labs will be screened for these genetic markers to provide a more complete picture of mold contamination present.
Commercial availability of the Roche ERMI qPCR Mold Detection Kit helps provide an objective and standardized result that will allow inspectors to provide highly informed recommendations to clients.
“We are acutely aware of the inferiority of spore-trap analysis and the direct benefits of DNA analysis utilizing real-time PCR,” said Ed Sobek, PhD, Chief Scientist of The Chiodo Companies.
“With the recent licensing by the EPA of Clean Air Lab to utilize real-time PCR analysis for DNA testing and our partnership with Roche Diagnostics, The Chiodo Companies continues to be at the forefront of new developments in the industry. This partnership will enable our two companies to drive the movement of the entire industry to this platform by ensuring lower cost of analysis, better results and the ability to better understand how molds impact human health,” Sobek added.
“At Roche Diagnostics we are committed to leveraging our diagnostic technologies and expertise to bring more accurate and efficient solutions to the field of environmental testing,” said Oliver Strobel, Director of New Business Development at Roche Diagnostics Applied Science.
“The release of our ERMI Kit is an exciting example of that commitment, and our strategic relationship with The Chiodo Companies is an important step in our plans to bring future integrated workflow solutions to this market,” he said.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019